TY - JOUR
T1 - Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases
AU - Tomitaka, Asahi
AU - Kaushik, Ajeet
AU - Kevadiya, Bhavesh D.
AU - Mukadam, Insiya
AU - Gendelman, Howard E.
AU - Khalili, Kamel
AU - Liu, Gang
AU - Nair, Madhavan
N1 - Funding Information:
This work was supported by National Institute of Health Grants NIH grants ( R01DA037838 , R01DA040537 , R01DA034547 and R01DA042706 ), the Major State Basic Research Development Program of China ( 2017YFA0205201 , 2014CB744503 and 2013CB733802 ), the National Natural Science Foundation of China ( 81422023 , 81371596 , 81672023 , U1705281 and U1505221 ), the Fundamental Research Funds for the Central Universities ( 20720160065 and 20720150141 ) and the Program for New Century Excellent Talents in University, China (NCET-13-0502). The authors also acknowledge the research facilities of Institute of NeuroImmune Pharmacology (INIP) and Advanced Materials Engineering Research Institute (AMERI) of Florida International University.
Funding Information:
This work was supported by National Institute of Health Grants NIH grants (R01DA037838, R01DA040537, R01DA034547 and R01DA042706), the Major State Basic Research Development Program of China (2017YFA0205201, 2014CB744503 and 2013CB733802), the National Natural Science Foundation of China (81422023, 81371596, 81672023, U1705281 and U1505221), the Fundamental Research Funds for the Central Universities (20720160065 and 20720150141) and the Program for New Century Excellent Talents in University, China (NCET-13-0502). The authors also acknowledge the research facilities of Institute of NeuroImmune Pharmacology (INIP) and Advanced Materials Engineering Research Institute (AMERI) of Florida International University.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/3
Y1 - 2019/3
N2 - Advanced central nervous system (CNS) therapies exhibited high efficacy but complete treatment of CNS diseases remains challenging owing to limited delivery of therapeutic agents to the brain. Multifunctional magnetic nanoparticles are investigated not only for site-specific drug delivery but also for theranostic applications aiming for an effective CNS therapy. Recently, surface engineering of magnetic nanoparticles was recognized as a crucial area of research to achieve precise therapy and imaging at molecular and cellular levels. This review reports state-of-the-art advancement in the development of surface-engineered magnetic nanoparticles targeting CNS diagnostics and therapies. The challenges and future prospects of magnetic theranostics are also discussed by considering the translation from bench to bedside. Successful translation of magnetic theranostics to the clinical setting will enable precise and efficient diagnostics and therapy to manage CNS diseases.
AB - Advanced central nervous system (CNS) therapies exhibited high efficacy but complete treatment of CNS diseases remains challenging owing to limited delivery of therapeutic agents to the brain. Multifunctional magnetic nanoparticles are investigated not only for site-specific drug delivery but also for theranostic applications aiming for an effective CNS therapy. Recently, surface engineering of magnetic nanoparticles was recognized as a crucial area of research to achieve precise therapy and imaging at molecular and cellular levels. This review reports state-of-the-art advancement in the development of surface-engineered magnetic nanoparticles targeting CNS diagnostics and therapies. The challenges and future prospects of magnetic theranostics are also discussed by considering the translation from bench to bedside. Successful translation of magnetic theranostics to the clinical setting will enable precise and efficient diagnostics and therapy to manage CNS diseases.
UR - http://www.scopus.com/inward/record.url?scp=85060737896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060737896&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2019.01.006
DO - 10.1016/j.drudis.2019.01.006
M3 - Review article
C2 - 30660756
AN - SCOPUS:85060737896
VL - 24
SP - 873
EP - 882
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 3
ER -